Plain-English translation of NCT06453044 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This study is testing a combination of two new medications — and — in people with follicular lymphoma (a type of blood cancer) that has come back after treatment or stopped responding to previous therapy. The trial will determine how safe and effective this medication combination is, and how many patients experience complete remission.
Many people with follicular lymphoma eventually experience their cancer returning or becoming resistant to standard treatments. This trial exists to find a new treatment option for these patients who have exhausted other therapies.
You likely qualify if…
You likely don't qualify if…
You will receive two medications: one given as an IV infusion over 30–90 minutes on the first day of each 3-week cycle, and another given as a subcutaneous injection (under the skin) on specific days. The first medication continues for up to 6 cycles, while the second continues for 8–17 cycles. Throughout the study, you'll have regular blood tests and imaging scans (CT, PET, or MRI) to monitor how you're responding. After treatment ends, you'll be followed up at 30 days and then for 3 years.
AI-generated summary from trial data · Jun 30, 2026 · Not medical advice
United States